Increased lysis of patient CD10-positive leukemic cells by T cells coated with anti-CD3 Fab' antibody cross-linked to anti-CD10 Fab' antibody.

No abstract is available for this paper.

• Publication year

  1991

• Venue

  Blood

• Publication date

  1991-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/BLOOD.V77.5.1044.1044PMID 1825287
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bispecific antibody: a tool for diagnosis and treatment of disease

  1990cited by this paper
• Cytotoxic T lymphocyte triggering via CD16 is regulated by CD3 and CD8 antigens. Studies with T cell receptor (TCR)-alpha beta+/CD3+16+ and TCR-gamma delta+/CD3+16+ granular lymphocytes.

  1990cited by this paper
• Induction of cytotoxicity in human T cells coated with anti-glioma x anti-CD3 bispecific antibody against human glioma cells.

  1990cited by this paper
• Preliminary trial of specific targeting therapy against malignant glioma.

  1990cited by this paper
• Bispecific F(ab′)2 monomer prepared with anti‐CD3 and anti‐tumor monoclonal antibodies is most potent in induction of cytolysis of human T cells

  1989cited by this paper
• An in-vitro model for tumor immunotherapy with antibody heteroconjugates.

  1988cited by this paper
• Characterization of interleukin 2-expanded human peripheral blood lymphocytes: not only NKH-1+-NK cells but also NKH-1+ and NKH-1- T cells are LAK effectors.

  1988cited by this paper
• Induction of NK cell activity against fresh human leukemia in culture with interleukin 2.

  1987cited by this paper
• Human K/natural killer cells targeted with hetero-cross-linked antibodies specifically lyse tumor cells in vitro and prevent tumor growth in vivo.

  1987cited by this paper
• Human T cells targeted with anti-T3 cross-linked to antitumor antibody prevent tumor growth in nude mice.

  1987cited by this paper
• Cytotoxicity of interleukin 2-activated lymphocytes for leukemia and lymphoma cells

  1986cited by this paper
• Cytotoxicity of interleukin 2-activated lymphocytes for leukemia and lymphoma cells.

  1986cited by this paper
• Activation of human peripheral blood mononuclear cells by anti-T3: killing of tumor target cells coated with anti-target-anti-T3 conjugates.

  1986cited by this paper
• Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis

  1986cited by this paper
• Specific targeting of human peripheral blood T cells by heteroaggregates containing anti-T3 crosslinked to anti-target cell antibodies

  1986cited by this paper
• Lymphokine-activated killer cells. Analysis of progenitors and effectors

  1986cited by this paper
• Specific lysis of human tumor cells by T cells coated with anti-T3 cross-linked to anti-tumor antibody.

  1986cited by this paper
• Lysis of lymphoma cells by autologous and allogeneic natural killer cells.

  1985cited by this paper
• Hybrid antibodies can target sites for attack by T cells

  1985cited by this paper
• Natural killer-mediated lysis of normal and malignant target cells, and its regulation by monocytes

  1985cited by this paper
• Heteroantibody duplexes target cells for lysis by cytotoxic T lymphocytes.

  1985cited by this paper
• Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody

  1985cited by this paper
• A cloned human T cell line cytotoxic for autologous and allogeneic B lymphoma cells

  1984cited by this paper
• Lysis of leukemia and lymphoma cells by autologous and allogeneic interferon-activated blood mononuclear cells.

  1983cited by this paper
• Continuous culture of T cells cytotoxic for autologous human leukaemia cells

  1979cited by this paper

• Antibody Therapies for Acute Myeloid Leukemia: Unconjugated, Toxin-Conjugated, Radio-Conjugated and Multivalent Formats

  2019cites this paper
• T cell engaging bispecific antibody (T‐BsAb): From technology to therapeutics

  2017cites this paper
• Derlin-1 Is Overexpressed on the Tumor Cell Surface and Enables Antibody-Mediated Tumor Targeting Therapy

  2008cites this paper
• CD3-CD28Costimulationas a Meansto AvoidingT CellPreactivationin Bispecific Monoclonal Antibody-based Treatment of Ovarian Carcinoma1

  2006cites this paper
• Simultaneous expression of different immunogenic antigens in acute myeloid leukemia.

  2000cites this paper
• Bispezifische Antikörper — Werkzeuge zur T-Zell Rekrutierung

  1998cites this paper
• The development of monoclonal antibodies for the therapy of cancer.

  1998cites this paper
• A cell surface molecule, JL1; a specific target for diagnosis and treatment of leukemias

  1998cites this paper
• Werkzeuge zur T -Zell Rekrutierung

  1998cites this paper
• CD3×CD19 bispecific antibodies and CD28 costimulation for locoregional treatment of low-malignancy non-Hodgkin’s lymphoma

  1997cites this paper
• CD3 x CD19 bispecific antibodies and CD28 costimulation for locoregional treatment of low-malignancy non-Hodgkin's lymphoma.

  1997cites this paper
• CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma.

  1996cites this paper
• Activation of T cell cytotoxicity against autologous common acute lymphoblastic leukemia (cALL) blasts by CD3xCD19 bispecific antibody.

  1996cites this paper
• Bispecific monoclonal antibody therapy of B-cell malignancy.

  1995cites this paper
• Bispecific antibody-mediated cytotoxicity by CD4+ and CD8(+)-activated T cells generated from leukemia patients after allogeneic bone marrow transplantation.

  1995cites this paper
• Killing of Autologous B-Lineage Malignancy Using CD3 x CD19 Bispecific Monoclonal Antibody in End Stage Leukemia and Lymphoma

  1994cites this paper
• Combination of interleukin-2-stimulated lymphocytes and bispecific antibodies that efficiently lyse leukemic cells does not affect bone marrow CD34-positive stem cell function in vitro.

  1994cites this paper
• Cytotoxicity of cytokine-induced killer cells coated with bispecific antibody against acute myeloid leukemia cells.

  1994cites this paper
• Killing of autologous B-lineage malignancy using CD3 x CD19 bispecific monoclonal antibody in end stage leukemia and lymphoma.

  1994cites this paper
• A bispecific antibody enhances cytokine-induced killer-mediated cytolysis of autologous acute myeloid leukemia cells.

  1993cites this paper
• Ca2+ response in single human T cells induced by stimulation of CD4 or CD8 and interference with CD3 stimulation.

  1993cites this paper
• Selective targeting of human lymphokine-activated killer cells by CD3 monoclonal antibody against the interferon-inducible high-affinity Fc gamma RI receptor (CD64) on autologous acute myeloid leukemic blast cells.

  1993influential citation
• Bispecific antibodies in lymphoma.

  1993cites this paper
• Lysis of malignant B cells from patients with B-chronic lymphocytic leukemia by autologous T cells activated with CD3 x CD19 bispecific antibodies in combination with bivalent CD28 antibodies.

  1993cites this paper
• Bispecific antibodies.

  1992cites this paper
• A bispecific antibody detects cytotoxic T lymphocytes of unknown antigen specificity in patients with granular lymphocyte‐proliferative disorders

  1992cites this paper
• In vitro Anti‐tumor Activity of Anti‐c‐erbB‐2 × Anti‐CD3ɛ Bifunctional Monoclonal Antibody

  1992cites this paper
• G19.4(alpha CD3) x B43(alpha CD19) monoclonal antibody heteroconjugate triggers CD19 antigen-specific lysis of t(4;11) acute lymphoblastic leukemia cells by activated CD3 antigen-positive cytotoxic T cells.

  1992cites this paper
• Anti-CD3 + interleukin-2 stimulation of marrow and blood: comparison of proliferation and cytotoxicity.

  1992cites this paper
• Bispecific anti-idiotype/anti-CD3 antibody therapy of murine B cell lymphoma.

  1991cites this paper
• Treatment of mice bearing BCL1 lymphoma with bispecific antibodies.

  1991cites this paper